Would AI Shrink The Market? The Data Said AI Could Grow It Instead.

A private equity firm owned a healthcare software platform Industry consolidation was accelerating. At the same time, larger platforms were building native capability that reduced the need for a standalone vendor manager. The sponsor needed a clear, defensible answer on whether AI threatened the business or extended it, built explicitly to inform its own investment thinking.

Where 29 actionable initiatives originated

Resultant interviewed stakeholders across every function of the company and ran seven discovery sessions covering topics from strategy to compliance. We followed up with four cross-functional workshops where 99 potential opportunities surfaced directly from the people who do the work every day. That process gave employees ownership over the ideas that came from their own departments, building buy-in into the roadmap from the start.

We evaluated each potential initiative with our structured scoring model, weighing business impact, competitive risk, feasibility, and cost. Twenty-nine actionable opportunities remained: five ready to deploy within months, eighteen lower-risk additions to the current roadmap, and six higher-value, longer-horizon bets.

We also measured the organization's ability to execute against an established maturity scale, placing the company in the Institutional stage today, one level below where it's capable of operating. Specialized talent, more than technology or leadership buy-in, was the gap standing between the two. The roadmap holds back the most ambitious tier of AI moves, fully autonomous systems replacing human judgment in relationship-driven work, until that gap closes.

A verdict the sponsor could act on

The engagement resolved into a single verdict: medium AI disruption risk on the defensive side, high opportunity on the offensive side, several of those opportunities pointing toward new revenue. That verdict is what let the sponsor carry a structured, evidence-based position directly into its own investment thinking, concrete enough for board conversations, ongoing portfolio oversight, and eventual exit or co-investor conversations.

The risk side of the verdict

Risk varies by function: commercial and client relationships carry the least AI risk, since the work depends on relationships hospital systems trust, not on tasks AI can easily replace. Benchmarking and advisory work carries mixed risk, durable as long as independence and cross-vendor comparison stay more valuable than a vendor's self-reported numbers. Vendor management operations carry the most risk, exposed to the same vendor consolidation and platform expansion driving the original question.

New revenue beyond risk mitigation

Further expanding value to the client, the team identified two opportunities to increase revenue streams, outside of any efforts related to AI.

For any healthcare software company, the useful answer isn't whether AI is a threat. It's which functions are exposed and which are safe, because that's what tells you where to act first.

 

Weighing whether AI strengthens or threatens a portfolio company's model? See how we approach AI strategy and readiness.

Ready to challenge your thinking?

Have a question or request for Resultant? Fill out the form and we'll get back to you quickly.


Insights delivered to your inbox